ISSN:
1525-1438
Source:
Blackwell Publishing Journal Backfiles 1879-2005
Topics:
Medicine
Notes:
Abstract. Vermorken JB, Landoni F, Pecorelli S, Piccart MJ, van derBurg MEL, ten Bokkel Huinink WW, George M, Greggi S, Rotmensz N. Phase II study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study. Int J Gynecol Cancer 1991; 1: 248–252.Twenty-nine patients with disseminated squamous cell carcinoma of the uterine cervix were treated with a 3 mg/m2 weekly i.v. bolus schedule of vindesine for 6 weeks (thereafter every 2 weeks). Twenty-seven patients were evaluable for response, 19 of whom had received prior chemotherapy (14 also vincristine). Five of the 27 patients (19%) showed a partial response, all being part of the 22 patients with only distant metastases. No objective response were observed among five patients who also had loco-regional recurrent disease. The median duration of response was 21 (11–58) weeks. Dose-limiting toxic effects were leukopenia and peripheral neuropathy. Vindesine warrants further study in combination chemotherapy protocols for cervical cancer.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1111/j.1525-1438.1991.tb00050.x
Permalink